FXYD5 and cancer: The meta-analysis I revealed that cancer patients with high tumoral dysadherin protein level face a three times higher risk of death (HR 3.08, 95% CI 1.88-5.06, p-value <0.000, both fixed and random effects models) compared to patients with low dysadherin level.